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Abstract
Background: Morbidity management is a core component of the global programme for the
elimination of lymphatic filariasis. In a double-blind clinical trial, the tolerability and efficacy of Daflon
(500 mg) + DEC (25 mg) or DEC (25 mg) alone, twice daily for 90 days, was studied in 26 patients
with bancroftian filarial lymphoedema.
Results: None of the patients in either drug group reported any adverse reaction throughout the
treatment period (90 days). Haematological and biochemical parameters were within normal limits
and there was no significant difference between the pre-treatment (day 0) and post-treatment (day
90) values. The group receiving Daflon showed significant reduction in oedema volume from day
90 (140.6 ± 18.8 ml) to day 360 (71.8 ± 20.7 ml) compared to the pre-treatment (day 0, 198.4 ±
16.5 ml) value. This accounted for a 63.8% reduction in oedema volume by day 360 (considering
the pre-treatment (day 0) as 100%). In the DEC group, the changes in oedema volume (between
day 1 and day 360) were not significant when compared to the pre-treatment (day 0) value. The
percentage reduction at day 360 was only 9%, which was not significant (P > 0.05).
Conclusion: This study has shown that Daflon (500 mg, twice a day for 90 days) is both safe and
efficacious in reducing oedema volume in bancroftian filarial lymphoedema. Further clinical trials are
essential for strengthening the evidence base on the role of this drug in the morbidity management
of lymphatic filariasis.
Background
Lymphatic filariasis (LF) is endemic in as many as 80
countries [1,2]. An estimated 1.1 billion people are at risk
of infection, and there are approximately 120 million
people with patent infection or disease round the globe
[3–5]. In India alone, 553 million people are estimated to
live in areas endemic for lymphatic filariasis and there are
approximately 21 million people with symptomatic
filariasis [6]. Progressive lymphoedema (from the early re-
versible stages to irreversible and complicated stages) as-
sociated with the increase in episodic attacks of acute
adenolymphangitis (ADL) [7] is the most important cause
of physical suffering, permanent disability and economic
loss [8–10]. It has been estimated that there are some
16.02 million cases of lymphoedema caused by LF global-
ly, and of these, 7.44 million (46.4%) live in India [3].
LF is recognized as one of six potentially eradicable diseas-
es [11] and in 1997, the World Health Assembly (WHA)
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passed a resolution calling for it's global elimination as a
public health problem [4,12].
The current strategy for the global elimination of LF rec-
ommended by the Global Alliance for the Elimination of
Lymphatic Filariasis (GAELF) [1] has two major compo-
nents: transmission control and morbidity management
[13].
Transmission control
The most important transmission control strategy being
implemented is the annual mass administration of single-
dose anti-parasitic drugs (albendazole with diethylcar-
bamazine citrate (DEC) in countries where onchocerciasis
or loiasis is not co-endemic with LF, or albendazole with
ivermectin in countries where onchocerciasis or loaiasis is
co-endemic with LF) to the entire at risk community,
aimed at a significantly reducing community parasite load
[14,15].
Morbidity management
For morbidity management, the current emphasis is on
use of an appropriate hygiene and skin care regimen, (pi-
oneered by Gerusa Dryer in Brasil), that lymphoedema
patients can use everyday [16] for the prevention of epi-
sodic attacks of adenolymphangitis (ADL) and progres-
sion of disease [2,17].
Availability of other measures for morbidity management
(such as drugs or physiotherapy or surgery) which can re-
duce oedema volume (along with appropriate hygiene
and skin care) will be important in the alleviation of suf-
fering and consequent improvement in psycho-social
condition of these patients.
Daflon, (micronized purified flavonoid fraction of Rutace-
ae aurantiae) [18] has been used in clinical practice to treat
a variety of lymphoedemas, such as post radical mastecto-
my oedema [19], chronic venous insufficiency [20],
haemorrhoids [21,22], varicose ulcers [23,24], post-phle-
bitic syndrome, dysfunctional uterine bleeding [25] and
idiopathic cyclic oedema syndrome [26].
To date, no clinical trials have been conducted to assess
the suitability of this drug in the treatment of filarial lym-
phoedema. In this paper, we are presenting our observa-
tions on the tolerability and efficacy of Daflon (500 mg,
twice a day for 90 days) in reducing oedema volume in pa-
tients with bancroftian filarial lymphoedema.
Materials and Methods
Selection of patients
Initially, patients with unilateral lower limb lymphoede-
ma were detected by conducting a morbidity survey in a
village known to be endemic for lymphatic filariasis near
Pondicherry in south India (recording Wuchereria bancrof-
ti microfilaria rate of 17.2%, an overall disease rate of
14.1%, lymphoedema rate of 6.3% and antigenaemia rate
of 28.6% using ICT card test; Vector Control Research
Centre – unpublished data). These patients were referred
to the Government General Hospital at Pondicherry,
where they were examined by a senior physician and re-
cruited to the study as per inclusion/exclusion criteria (Ta-
ble 1).
In the natural history of LF, many patients with lym-
phoedema do not have demonstrable microfilaraemia
[27–29] nor antigenaemia [30]. Therefore, in areas which
are considered to be highly endemic for LF, (such as in the
current study), cases of unilateral lymphoedema are con-
sidered to be of filarial origin by exclusion of all other
conditions, (such as venous insufficiency and varicose ul-
cers, which could also present with lymphoedema), by
careful history taking and clinical examination, using the
clinical criteria for diagnosis and grading recommended
by the World Health Organization (WHO) [31].
Study design and treatment regimen
Twenty-six patients (18 female and 8 male patients) be-
tween the ages of 20 and 55 years, (mean 39 years), who
met the inclusion / exclusion criteria [Table 1], and who
had given written informedconsent, were admitted to the
Government General Hospital at Pondicherry for a period
of four days and randomly allocated into one of two drug
groups:
Group A: Daflon (500 mg) + DEC (25 mg) twice a day for
90 days
Group B: DEC (25 mg) twice a day for 90 days.
The drugs were repackaged in look-alike capsules contain-
ing either Daflon (500 mg) + DEC (25 mg) or DEC (25
mg).
The appropriate drug regimen was administered to the pa-
tients twice daily (morning and evening) from day 1 to
day 3 (three days excluding day 0, i.e. day of admission)
of hospitalization, under the direct supervision of the
medical team. Patients were discharged on the morning of
day 4 with a pack of the appropriate drug capsules (for the
next 12 days: to complete the treatment up to day 15). The
patients were educated and instructed by the physician
and a social worker to comply with the dosage schedule
and were asked initially to report every fortnight for meas-
urement of oedema volume and to receive a further sup-
ply of drug capsules for the proceeding 15 days, up to day
90. Thereafter, patients were requested to attend 3 subse-
quent times, day(s) 180, 270 and 360 to allow measure-
ment of oedema volume.Filaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/5
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Ethical considerations
The study conformed to the principles of Helsinki Decla-
ration II [32], the Guidelines for Good Clinical Practice
(GCP) for Trials on Pharmaceutical Products [33] and the
guidelines of the Indian Council of Medical Research for
bio-medical research involving human subjects [34]. Fur-
thermore, the study was approved by the Institutional Sci-
entific Advisory Committee and the Institutional Ethical
Committee. The study was "blind" to the extent that pa-
tients, clinicians evaluating the adverse effects, and labo-
ratory staff carrying out the laboratory tests were unaware
of the individual treatment schedules. Blinding and cod-
ing of the drugs was done by an independent monitor (a
senior scientist who was not an investigator) after repack-
ing in look-alike capsules by a pharmaceutical company
in Pondicherry. The codes were broken only after comple-
tion of the study.
Assessment of results
Tolerability
All patients were clinically monitored for any adverse re-
actions (such as abdominal pain, nausea, vomiting, chest
pain, arthralgia, diarrhoea, fever, headache, myalgia and
chills) at 8 hourly intervals for first 24 hours and thereaf-
ter every 24 hours for further two days (until the end of
day 3). All systemic reactions, if any, were recorded in a
pre-designed form. Laboratory investigations on haema-
tology and biochemistry parameters (haemoglobin con-
centration, total white blood count, differential count,
absolute eosinophil count, erythrocyte sedimentation
rate, packed cell volume, blood urea, sugar, bilirubin, cre-
atinine, cholesterol, serum sodium, potassium, chloride,
protein, albumin, globulin, glutamic pyruvic transami-
nase, alkaline phosphatase) were assessed on day 0, (pre-
treatment), and on completion of treatment (day 90).
Efficacy
Oedema volume was recorded using a water displacement
method [35] on day 0 (pre-treatment) and every fortnight
from day 15 to day 90, and thereafter every 3 months on
day(s) 180, 270 and 360.
On day 0, during the clinical history taking, the senior
physician enquired about patient experiences of ADL at-
tacks, and their frequency in the past 6 months prior to
admission. At each follow-up point the patients were
asked about the occurrence of ADL attacks in the period
between the visits, and were also clinically examined for
signs and symptoms of acute disease, as per WHO criteria
[31].
Statistical analysis
The mean age of the patients and the mean frequency of
ADL attacks (6 months prior to treatment) in the two drug
groups were compared using independent t test. The sta-
tistical significance in the difference between the mean
oedema volume was calculated using paired t-test.
Results
A total of 26 ambulatory patients with unilateral lym-
phoedema, (selected as per inclusion and exclusion crite-
ria [Table 1]), were recruited to the study; 13 in each drug
group (Group A: Daflon (500 mg) + DEC (25 mg) twice a
day, for 90 days; Group B: DEC (25 mg) twice a day, for
90 days). The mean age (± SD) of the patients in the Da-
flon + DEC group was 40 (± 11.5) years (range 20–55)
and in the DEC group it was 38 (± 6.8) years (range 24–
50) (P > 0.05 between the two groups). There were 12 pa-
tients with grade II oedema and one patient with grade I
oedema in each drug group. There was no significant dif-
ference in the pre-treatment (day 0) mean oedema vol-
ume (± SEM) between the Daflon + DEC (198.4 ± 16.5
ml) and the DEC alone (272.9 ± 48.0 ml) groups (P >
Table 1: Inclusion/exclusion criteria used for recruitment of patients in the study.
Inclusion criteria Exclusion criteria
a) Patients with unilateral lower limb lymphoedema (of either grade I/II minimum for six 
months†) from area highly endemic for bancroftian filariasis.
a) Haemoglobin less than 10 gm/dl or haematocrit < 30%.
b) Patients looking apparently healthy except as (a) above and with normal body weight as 
per age.
b) Clinical exclusion of patients with lymphoedema due to any other known 
aetiology other than filariasis (such as venous insufficiency, varicose ulcers).
c) Patients with normal electro-cardiogram (ECG).
d) Patients with normal chest X-ray. c) Patients presenting with acute adenolymphangitis at the time of recruitment.
e) Results within normal limits in routine stool and urine examination. d) Patients with a history of taking Daflon or DEC in the past 3 months.
f) Results within normal limits for haemoglobin concentration, total white blood cell count, 
differential count, absolute eosinophil count, erythrocyte sedimentation rate, packed cell 
volume.
e) Symptoms / signs of any other chronic illness
g) Results within normal limits for blood urea, sugar, bilirubin, creatinine, cholesterol, 
serum sodium, potassium, chloride, protein, albumin, globulin, pyruvic transaminase, alka-
line phosphatase.
f) Patients with a history of any drug intolerance, reaction or allergy.
†As per diagnostic criteria of WHO, 1992 (Ref. No. [31]). Grade I: oedema reversible on elevation. Grade II: oedema not reversible on elevation, 
skin not thickened.Filaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/5
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0.05). All the 26 patients completed the full 90 day treat-
ment schedule.
Tolerability
None of the patients in either study group complained of
any adverse reaction during the 90 days of treatment. The
haematological and biochemical parameters were within
normal limits for all patients, and did not vary significant-
ly between pre-treatment (day 0) and on completion of
treatment (day 90) (data not shown).
Efficacy
The mean oedema volume (± SEM) in the Daflon + DEC
group was 140.6 (± 18.8) ml at the end of treatment peri-
od (day 90) and it was 71.8 (± 20.7) ml at the end of the
follow-up period (day 360) (Figure 1). There was a signif-
icant difference in the mean oedema volume on day 90
and on day 360 in comparison to the pre-treatment value
(198.4 ± 16.5 ml on day 0, P < 0.05) (Table 2). The mean
oedema (± SEM) volume in the DEC group was 272.9 ±
48.0 ml the end of the follow-up period (day 360) (Figure
1). There was no significant difference in the mean oede-
ma volumes on day 90 and on day 360 in comparison to
the pre-treatment value (272.9 ± 48.0 ml on day 0, P >
0.05).
The percentage change of oedema volume in comparison
to pre-treatment (day 0) (considering day 0 volume as
100%) in the two treatment groups is shown in Figure 2.
It was observed that in the Daflon + DEC group the oede-
ma volume reduced by 29.1% at the end of treatment pe-
riod (day 90) and by 63.8% at the end of the follow-up
period (day 360). On the other hand, in the DEC group
the percentage reduction was nil at the end of the treat-
ment period (day 90) and it was 9% at the end of the fol-
low-up period (day 360).
Figure 1
Comparison of changes in mean (± SEM) oedema volume (in ml) over 360 days between patients treated with Daflon (500 mg) 
+ DEC (25 mg), and patients treated with DEC (25 mg), twice daily for 90 days. Day 0: pre-treatment Day 1 – day 90 period of 
treatment Day 91 – day 360 period of follow-up *P = < 0.05 vs. day 0 **P = < 0.005 vs. day 0 ***P = < 0.001 vs. day 0Filaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/5
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Comparison of the patterns of change in the day-specific
mean oedema volume (Figure 1) and its percentage
change (considering day 0 as 100%) (Figure 2) between
the two treatment groups (Table 2) showed that in the Da-
flon + DEC group, maximum reduction was observed be-
tween day 75 to day 180 (significant reduction in oedema
volume; t = 3.31, P < 0.01) and stabilized thereafter (no
significant difference in oedema volume between day 180
versus day 270 or between day 180 versus day 360, P >
0.05). In the DEC group, the mean oedema volume was
more or less stable through out the observation period
(Table 2).
In the 6 month period prior to starting the treatment, the
mean frequency of episodic ADL attacks (± SD) was 0.9 ±
1.1 in the Daflon + DEC group and it was 0.6 ± 0.9 in the
DEC group (P > 0.05 between the two groups). None of
the patients in either of the drug groups suffered from an
ADL attack through out the treatment and follow-up peri-
od (i.e. between day 1 and day 360).
Discussion
The World Health Organisation has targeted lymphatic
filariasis for elimination as a public health problem by the
year 2020 [1,2]. India, which has the highest burden of LF,
has set a target for national elimination of LF by the year
2015 [36]. Although annual mass administration of sin-
gle-dose anti-filarial drugs to entire endemic communities
for the control of transmission of lymphatic filariasis is
being implemented in many counties, including India,
(under which approximately 50 million citizens are cur-
rently being covered annually) [2,15], morbidity manage-
ment [13] aimed at the alleviation of suffering of the
individual patients has, in many countires, only recently
begun to be addressed.
There is no doubt that the introduction of an appropriate
hygiene and skin care regimen that patients can practice in
their own environment will be most important in provid-
ing long term gains in the management of their morbidity.
However, realisation of this strategy in many communi-
ties (living in rural and urban settings) in different endem-
ic countries with wide socio-economic diversity remains a
major challenge [17].
While the above strategy is being implemented, it is im-
portant to develop other measures, which could reduce
oedema volume in patients with filarial lymphoedema,
and, which can be integrated alongside a hygiene and skin
care regimen.
Although, surgical procedures have been developed for
filarial lymphoedema cases [37,38], these can only be per-
formed in a few specialized centers, where expertise is
available. Furthermore, it is costly and it has been ob-
served that sustaining the gains achieved by surgery de-
pends on the ability to prevent subsequent ADL episodes
(by following a hygiene and skin care regimen) [38].
Physiotherapeutic measures such as manual massage,
pneumatic compression and interferential current therapy
have been found to be useful in odemea volume reduc-
tion in other secondary lymphoedema cases [39,40,43],
however, these have yet to be properly evaluated in the
management of filarial lymphoedema. Interferential cur-
rent therapy showed significant oedema reduction in bru-
gian filarial lymphoedema cases [41]. Although,
pneumatic compression also results in oedema volume re-
duction, the results are not sustained [42]. Manual mas-
sage could be most useful as a self-help measure [43], but
objective data are yet to be generated in LF cases. Of the
chemotherapeutic agents investigated previously, 5,6 ben-
Table 2: Comparison of the day specific mean oedema volume between patients treated with Daflon (500 mg) + DEC (25 mg) and 
patients treated with DEC (25 mg), twice daily for 90 days.
Days of comparison Daflon 500 mg + DEC DEC
t – value P value t – value P value
day 0 vs. day 75 0.316 0.758 -0.140 0.891
day 0 vs. day 90 2.928 0.013 0.001 0.999
day 0 vs. day 180 4.149 0.002 0.521 0.612
day 0 vs. day 270 4.989 < 0.001 0.156 0.879
day 0 vs. day 360 6.959 < 0.001 0.428 0.676
day 75 vs. day 90 2.574 0.026 0.433 0.673
day 75 vs. day 180 3.309 0.007 1.291 0.221
day 180 vs. day 270 0.621 0.547 -1.003 0.336
day 270 vs. day 360 0.325 0.751 -0.006 0.996
Day 0: pre-treatment Day 1 – day 90: period of treatment Day 91 – day 360: period of follow-upFilaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/5
Page 6 of 9
(page number not for citation purposes)
zo-alpha-pyrone was most promising. In a double-blind
placebo controlled study on bancroftian filarial lym-
phoedma cases in south India, it was observed that 5,6
benzo-alpha-pyrone (given at the dosage of 200 mg twice
daily) resulted in significant reduction in oedema volume
(63% in grade II cases) at the end of a two year treatment
period [44]. The efficacy of this drug has also been dem-
onstrated in a study in China [45]. However, 5,6 benzo-
aplha-pyrone cannot be currently recommended for use
as the drug has been shown to be hepato-toxic [46].
Earlier studies have shown that DEC has limited role in
the management of filarial lymphoedema. In areas en-
demic for burgian filariasis in Indonesia considerable im-
provement in lymphoedema, including reversal of
elephantiasis, has been reported [47]. However, these ob-
servations were based on community studies and objec-
tive measurement of oedema volume was not carried out.
A significant reduction in oedema volume was reported
with repeated courses of DEC along with supportive
measures (such as pneumatic compression, use of crepe
bandage etc.) in a study, again on brugian filarial lym-
phoedema cases, from south India [48]. However, this
was an open trial and it is not possible to differentiate the
effect of DEC alone from that of the supportive measures.
In bancroftian filarial lymphoedema cases, long term
DEC therapy (6 mg /kg /day in two divided doses for 2
years) resulted in reduction in oedema volume ranging
only between 3 to 7 % in different grades of oedema [44].
A double blind clinical trial with single dose DEC (6 mg /
kg body weight) or ivermectin (400 mg / kg body weight)
did not show any significant change in oedema volume in
bancroftian filarial lymphoedema cases over a one-year
follow-up period (Vector Control Research Centre – un-
published data). In the current study, DEC treatment
alone at the dosage of 25 mg twice a day for 90 days did
Figure 2
Comparison of percentage change in oedema volume (in ml) over 360 days between patients treated with Daflon (500 mg) + 
DEC (25 mg), and patients treated with DEC (25 mg), twice daily for 90 days. Day 0: pre-treatment Day 1 – day 90: period of 
treatment Day 91 – day 360: period of follow-up Day 0 oedema volume is considered as 100% *** P = < 0.001 vs. day 0Filaria Journal 2003, 2 http://www.filariajournal.com/content/2/1/5
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not result in significant change oedema volume in filarial
lymphoedema cases. Freedman et al., using lymphoscin-
tigraphy did not observe any improvement in lymphatic
pathology after two courses of DEC (for 12 days each) in
bancroftian filarial lymphoedema cases [49]. Further-
more, DEC did not reduce the incidence of episodic ADL
attacks in individual lymphoedema cases [50,51] as well
as in the community after mass drug administration [52].
These results suggest the limitations of DEC in the mor-
bidity management in LF.
This is the first report of a clinical trial on the tolerability
and efficacy of Daflon in filarial lymphoedema cases. Da-
flon is known to be phlebotonic, it reduces capillary per-
meability and has an anti-lipidaemic effect [19,26]. This
drug is known to be safe and without any adverse reaction
in the dosage of 2 tablets of 500 mg each per day, and it
has been given up to one-year period [53,54]. The results
of the current study showed that there was neither any ad-
verse reaction during the 90 days treatment period nor
any significant change between the pre-treatment (day 0)
and post-treatment (day 90) haematological or biochem-
ical parameters in any of the patients (which were within
normal limits). This demonstrates that Daflon (500 mg,
twice a day for 90 days) is safe, well tolerated, and can be
used up to 90 days in patients with filarial lymphoedema.
Furthermore, the drug is also efficacious, reflected by a sig-
nificant reduction in oedema volume of 63.8% (recorded
between day 0 and day 360, inclusive of 90 days of treat-
ment period) (Figure 2). A significant reduction in oede-
ma volume was detected by the end of day 90 (Table 2).
In other clinical conditions, appreciable change has been
detected between 6 weeks to 6 months [55]. The pattern
of change in oedema volume showed a marked reduction
from day 75 until day 180 (Figure 1), after which the
change was marginal (Table 2). This could suggest that re-
peat course(s) may be required for further decrease in
oedema volume. Although Daflon was given along with
DEC in the current study, since DEC alone did not show
any significant reduction in oedema volume (Table 2, Fig-
ure 1), the results seen in the former group is likely to be
due to Daflon.
None of the patients in either drugs group suffered from
an ADL attack during the treatment and follow-up period.
The reason for this, however, is not clear. Although DEC,
(25 mg twice a day for 90 days), was given to all patients,
it is difficult to assign this effect to DEC, as previous expe-
rience, in both hospital and community studies, did not
favour this [50–52]. All the patients were also from a lim-
ited geographical area with similar environmental and so-
cio-economic conditions having similar risk for ADL.
None of the patients were advocated a specific hygiene
and skin care regimen as a part of the protocol (since this
is not yet a routine measure advocated by the National
Filariasis Control Programme [56] and also as this could
confound the results of effects of the drug (however, for
ethical reasons all patients were educated in an appropri-
ate hygiene and skin care regimen after completion of the
study)).
We conclude that Daflon (500 mg, twice a day for 90
days) is both safe and efficacious in reducing oedema vol-
ume in filarial lymphoedema. DEC, at the dosage given,
did not result in any significant change in oedema vol-
ume. However, as the current study was limited to a few
patients in south India (and did not have an arm of Da-
flon alone) further clinical trials (preferably multi-centre)
with larger numbers of patients need to be carried out
(and should address the effect of Daflon on lymphatic pa-
thology). This is essential for strengthening the evidence
base on the use of Daflon in the management of filarial
lymphoedema, before recommending its use in morbidity
management to the Global Programme for the Elimina-
tion of Lymphatic Filariasis.
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